All In Biotech

Drug Trial Radar · NCT02552238

Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142

A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography With Dobutamine for the Diagnosis of Coronary Artery Disease

Last checked: Nov 20, 2026Latest source record: Jul 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

174

Actual

Start

Oct 12, 2015

Primary completion

Jun 22, 2017

Study completion Feb 25, 2018

Sponsor

Lead sponsor
Bracco Diagnostics, IncIndustry
Sponsor type
Industry
First posted
Sep 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.

Conditions

  • Coronary Artery Disease

Interventions

  • LumasonDrug

    Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and Specificity of Lumason Enhanced Dobutamine Stress Echo (DSE) for Detection or Exclusion of Coronary Artery Disease (CAD)Time frame: Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography were performed
  2. Reader-Specific Percentages of Participants Identified as Having a Critical Shift From Suboptimal to Optimal Echocardiographic ImagesTime frame: Participants were followed until they had coronary angiography or up to 6 months post dose to collect clinical information on cardiac events if no coronary angiography was performed

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Coastal Multi-Specialty Research, Coastal Heart Medical Group

    Santa Ana, California

  • Alfieri Cardiology

    Wilmington, Delaware

  • Homestead Cardiac and Vein Center

    Homestead, Florida

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • St. Louis University Hospital

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Duke University Medical Center Cardiac Diagnostic Unit

    Durham, North Carolina

  • University of Texas Medical Branch at Galveston

    Galveston, Texas

  • Cliniques Universitaires Saint-Luc Unité de Pathologie Cardio-Vasculaire / Cardiologie

    Brussels, Belgium

  • Antwerp University Hospital

    Edegem, Belgium

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Hammersmith Hospital

    London, United Kingdom

  • Northwick Park Hospital

    Harrow, Middlesex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.